Sphera Funds Management LTD. purchased a new stake in NuCana PLC Sponsored ADR (NASDAQ:NCNA) during the 3rd quarter, according to the company in its most recent 13F filing with the Securities & Exchange Commission. The firm purchased 50,000 shares of the company’s stock, valued at approximately $919,000. Sphera Funds Management LTD. owned 0.16% of NuCana PLC Sponsored ADR at the end of the most recent quarter.

Separately, Baillie Gifford & Co. acquired a new stake in shares of NuCana PLC Sponsored ADR in the third quarter valued at approximately $8,266,000. Hedge funds and other institutional investors own 10.38% of the company’s stock.

Shares of NuCana PLC Sponsored ADR (NCNA) opened at $12.17 on Friday. NuCana PLC Sponsored ADR has a 12 month low of $9.64 and a 12 month high of $19.95.

Several equities research analysts have commented on the stock. William Blair assumed coverage on shares of NuCana PLC Sponsored ADR in a research note on Monday, October 23rd. They issued an “outperform” rating on the stock. Citigroup Inc. assumed coverage on shares of NuCana PLC Sponsored ADR in a research note on Monday, October 23rd. They issued a “buy” rating and a $23.00 price target on the stock. Cowen Inc assumed coverage on shares of NuCana PLC Sponsored ADR in a research note on Monday, October 23rd. They issued an “outperform” rating on the stock. Finally, Jefferies Group LLC assumed coverage on shares of NuCana PLC Sponsored ADR in a research note on Monday, October 23rd. They issued a “buy” rating and a $25.00 price target on the stock.

COPYRIGHT VIOLATION WARNING: This article was posted by Watch List News and is the sole property of of Watch List News. If you are accessing this article on another domain, it was copied illegally and reposted in violation of U.S. & international trademark & copyright laws. The legal version of this article can be accessed at https://www.watchlistnews.com/sphera-funds-management-ltd-purchases-new-position-in-nucana-plc-sponsored-adr-ncna/1723452.html.

NuCana PLC Sponsored ADR Profile

NuCana PLC is a clinical-stage biopharmaceutical company. The Company is focused on improving treatment outcomes for cancer patients by applying its phosphoramidate chemistry technology. The Company utilizes its ProTide technology to develop medicines to overcome cancer resistance mechanisms and generate much higher concentrations of anti-cancer metabolites in cancer cells.

Want to see what other hedge funds are holding NCNA? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for NuCana PLC Sponsored ADR (NASDAQ:NCNA).

Receive News & Ratings for NuCana PLC Sponsored ADR Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for NuCana PLC Sponsored ADR and related companies with Analyst Ratings Network's FREE daily email newsletter.